HIV Treatment
EACS 2017: New European Guidelines Cover HIV, Hepatitis C, and Related Conditions
- Details
- Category: HIV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Keith Alcorn
Everyone with HIV and hepatitis C virus (HCV) coinfection should receive direct-acting antiviral therapy for hepatitis C and should receive the same treatment regimens for hepatitis C as people with HCV monoinfection, new European guidelines issued at the 16th European AIDS Conference recommend.
EACS 2017: Fostemsavir Controls Viral Load in Half of People with Highly Drug-Resistant HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Keith Alcorn
Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the recent 16th European AIDS Conference in Milan.
EACS 2017: European Cure Review Concentrates on HIV Therapeutic Vaccines
- Details
- Category: Search for a Cure
- Published on Friday, 17 November 2017 00:00
- Written by Gus Cairns
A cure for HIV would almost inevitably have to involve a vaccine to improve the body’s natural ability to control HIV, speakers said at a recent seminar on European HIV cure research. The STEPS seminar, put on by the European AIDS Treatment Group (EATG) ahead of the European AIDS Conference in Milan in October, also heard that, in the words of EATG member and European Community Advisory Board chair Giulio Maria Corbelli, "Cure research reminds us of the importance of patient involvement from the very earliest phases of the development of treatment and prevention."
Coverage of IDWeek 2017
- Details
- Category: HIV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2017, held October 4-8, 2017, in San Diego.
- Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV
- Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year
11/30/17
Coverage of the 16th European AIDS Conference
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com and NAM coverage of the 16th European AIDS Conference (EACS 2017), October 25-27 2017, in Milan.
More Articles...
- EACS 2017: Boosted Protease Inhibitor + Lamivudine Effective for HIV Maintenance Treatment
- EACS 2017: ABX464 Reduces HIV Reservoir But Does Not Delay Vial Rebound
- EACS 2017: Symtuza as Effective as Multi-Pill Combination in Previously Untreated People with HIV
- EACS 2017: How a London Clinic Reduced New HIV Infections by 90%
Web Design and Development by